Navigation Links
ADVENTRX Announces Restructuring and Cost Reduction Initiatives
Date:10/20/2008

essary to meet its goals, including funding the continued development and commercialization of ANX-530 or ANX-514; the risk the FDA will determine that ANX-530 and Navelbine are not bioequivalent, including as a result of performing pharmacokinetic equivalence analysis based a patient population other than the population on which ADVENTRX based its analysis; the risk that the on-going clinical study of ANX-514 does not demonstrate pharmacokinetic equivalence or bioequivalence; the risk of investigator bias in reporting adverse events as a result of the open-label nature of the ANX-530 bioequivalence clinical study, including bias that increased the reporting of adverse events associated with Navelbine and/or that decreased the reporting of adverse events associated with ANX-530; difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ANX-530 and ANX- 514, including validating commercial manufacturers and suppliers and the potential for automatic injunctions regarding FDA approval of ANX-514; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings, including prior to the submission or the approval of an NDA for ANX-530 and ANX-514; the risk that the performance of third parties on whom ADVENTRX relies to conduct its studies or evaluate the data, including clinical investigators, expert data monitoring committees, contract laboratories and contract research organizations, may be substandard, or they may fail to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date wh
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
2. ADVENTRX Settles Dispute With Former Licensee
3. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. ADVENTRX Appoints Vice President of Manufacturing
5. ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
6. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
7. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
8. Eric K. Rowinsky Joins ADVENTRX Board of Directors
9. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
10. ADVENTRX Announces Consolidation of Clinical and Management Positions
11. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... 20, 2015 Research and Markets ... the "2015 Global Survey on Flow Cytometry ... The primary goal of this research is ... and reagents. Key information the survey seeks to ... flow cytometers, predominantly used applications for flow cytometers, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
... EL SEGUNDO, Calif., Nov. 16 Medical and technical ... on the International Space Station. Their efforts will help ... what might be experienced in a future mission to ... astronaut health during space exploration missions and provide us ...
... , LANSING, Mich., Nov. 16 Neogen Corporation (Nasdaq: NEOG ... 3-for-2 stock split. With the split, shareholders of record on Nov. ... two shares held. , The stock split will be effected ... in newly issued common stock on Dec. 15, 2009. As of ...
... , , SEATTLE, Nov. 16 ... "Company") today announced that the Company,s product candidate PX-866, ... Information, Inc., as one of the Top 10 most ... partnering. , The selection was made by an independent ...
Cached Biology Technology:Wyle Personnel Take Part in Important Studies Aboard the International Space Station 2Wyle Personnel Take Part in Important Studies Aboard the International Space Station 3Neogen Announces 3 for-2 Stock Split 2Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover 2Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover 3
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
(Date:4/2/2015)... April 2, 2015 Fingerprint Cards ... sensor FPC1025 from the distributor World Peace Industrial Group ... Q2 2015 although the major part of the shipments ... be used by smartphone manufacturers in China ... included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... will use a $120,000 grant from the Foundation for AIDS ... cells it attacks have evolved together over time. The goal ... When HIV infiltrates cells, the virus hijacks its host,s ... has been recently found that the retrovirus hijacks about 1,000 ...
... by researchers at the Montreal Neurological Institute (MNI), ... provides vital insights into the neurological basis of ... some instances develop various addictions when undergoing medical ... 25) issue of the scientific journal Neuron ...
... new statistical model could be used to predict an ... the Children,s Hospital Informatics Program (CHIP). Using genetic information ... predictive model could estimate an individual,s overall risk of ... -- with 86 percent accuracy. The findings are reported ...
Cached Biology News:Evolutionary biologist will study HIV with grant from AIDS research foundation 2Addiction: Insights from Parkinson's disease 2Predicting risk of stroke from one's genetic blueprint 2
... is designed to purify double-stranded DNA (dsDNA) generated ... PCR. The process is simple and fast. DNA ... can be efficiently purified and concentrated. The DNAclear ... bound to the Microfilter Cartridge in the presence ...
GOAT ANTI PPP2R5B...
acridine orange 10-nonyl bromide (nonyl acridine orange)...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure grade propidium iodide is greater than or equal to 98% pure by HPLC....
Biology Products: